Skip to content
Triangle logo TriangleGet started
← Full study record

NCT01062230 · OUTCOME

Maximum Percent Change From Baseline in Intact Parathyroid Hormone Levels on Day 1

Bone Effect of Bortezomib in Patients With Relapsed/Refractory Multiple Myeloma · Source last updated 2015-04-06

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
NUMBER
Unit
% change
Interval / dispersion
Not reported
Time frame
Baseline and Day 1

What was measured

All patients received 0.7 mg/m2 of bortezomib on days 1, 4, 8 and 11 of a 21 day cycle, for maximum of three cycles for an average of 18 months. Intact Parathyroid hormone was measured in patients with relapsed/refractory myeloma for osteoblast activation. Other bone markers were examined using similar methods.

Groups in this outcome

All Patients

All participants enrolled. Bortezomib (Velcade): Bortezomib will be administered as a 3-5 second bolus IV injection at the dose of 0.7 mg/m2 on days 1, 4, 8, and 11 q. 21 days times three cycles. Patients will undergo three 21-day cycles.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
All Patients6

Reported measurements

Subject 1
Values in % change · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
All Patients113.5Not reportedNot reportedNot reportedNot reported
Subject 2
Values in % change · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
All Patients-9.09Not reportedNot reportedNot reportedNot reported
Subject 3
Values in % change · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
All Patients30.7Not reportedNot reportedNot reportedNot reported
Subject 4
Values in % change · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
All Patients-50Not reportedNot reportedNot reportedNot reported
Subject 5
Values in % change · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
All Patients93.6Not reportedNot reportedNot reportedNot reported
Subject 6
Values in % change · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
All Patients-53.5Not reportedNot reportedNot reportedNot reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        value
        113.5
    title
    Subject 1
  2. categories
    1. measurements
      1. group Id
        OG000
        value
        -9.09
    title
    Subject 2
  3. categories
    1. measurements
      1. group Id
        OG000
        value
        30.7
    title
    Subject 3
  4. categories
    1. measurements
      1. group Id
        OG000
        value
        -50
    title
    Subject 4
  5. categories
    1. measurements
      1. group Id
        OG000
        value
        93.6
    title
    Subject 5
  6. categories
    1. measurements
      1. group Id
        OG000
        value
        -53.5
    title
    Subject 6
denoms
  1. counts
    1. group Id
      OG000
      value
      6
    units
    Participants
description
All patients received 0.7 mg/m2 of bortezomib on days 1, 4, 8 and 11 of a 21 day cycle, for maximum of three cycles for an average of 18 months. Intact Parathyroid hormone was measured in patients with relapsed/refractory myeloma for osteoblast activation. Other bone markers were examined using similar methods.
groups
  1. description
    All participants enrolled. Bortezomib (Velcade): Bortezomib will be administered as a 3-5 second bolus IV injection at the dose of 0.7 mg/m2 on days 1, 4, 8, and 11 q. 21 days times three cycles. Patients will undergo three 21-day cycles.
    id
    OG000
    title
    All Patients
param Type
NUMBER
reporting Status
POSTED
time Frame
Baseline and Day 1
title
Maximum Percent Change From Baseline in Intact Parathyroid Hormone Levels on Day 1
type
PRIMARY
unit Of Measure
% change

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice